#SFHS2607855ADecree of 26 March 2026 amending the list of pharmaceutical specialties reimbursable to social insured persons
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This French decree extends national health insurance reimbursement to spironolactone-containing medicines for a new indication: treatment of hirsutism in adults, either as monotherapy or in combination with other drugs. The measure adds twelve specific Aldactone and generic Spironolactone Pfizer presentations (25 mg, 50 mg and 75 mg tablets in packs of 30 or 90) to the reimbursable list under the new extended indication. The change takes legal effect upon publication in the Journal Officiel and applies to all social-security insured persons in France. It widens patient access to an established potassium-sparing diuretic for an endocrine/cosmetic condition without altering pricing, posology or safety rules.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Extension of reimbursement to treatment of hirsutism in adults (monotherapy or combination)
- Twelve specific spironolactone presentations (25 mg, 50 mg, 75 mg in B/30 and B/90 packs) added to the reimbursable list
- All listed products are manufactured by Laboratoires Pfizer
+ 3 more changes with Pro
Obligations
What this law requires
Add twelve specified spironolactone pharmaceutical presentations (Aldactone and generic Spironolactone Pfizer in 25 mg, 50 mg, and 75 mg formulations in packs of 30 or 90) to the national list of reimbursable pharmaceuticals under the new indication of hirsutism treatment in adults
Extend national health insurance reimbursement coverage for the twelve listed spironolactone presentations to cover treatment of hirsutism in adults as monotherapy or in combination with other drugs
Apply the reimbursement extension to all socially-insured persons in France without restriction
Publish the decree in the Journal Officiel de la République française to make it legally effective
Make the reimbursement extension legally effective upon publication in the Journal Officiel without requiring additional regulatory steps or implementation delays